RQ Biotechnology

Executive Summary

RQ Biotechnology is a UK-based private biotech company focused on developing long-acting monoclonal antibodies for seasonal influenza. Founded in 2021, the company aims to provide immediate, potent, and lasting protection against severe disease caused by influenza viruses. Their platform leverages antibody engineering to extend half-life and enhance potency, potentially offering a single-dose prophylactic or therapeutic option that could be more convenient than current annual vaccines. While still in early preclinical or discovery stages, RQ Bio addresses a significant unmet need for more durable influenza protection. The company's current stage and lack of disclosed funding or pipeline details suggest it is pre-revenue and likely seeking capital to advance its lead candidate into clinical development.

Upcoming Catalysts (preview)

• H2 2026Series A Funding Announcement60% success
• H1 2027Lead Candidate Preclinical Data Disclosure50% success
• 2028First Clinical Trial Initiation (Phase 1)30% success